Work

Simultaneous Initiation of Dolutegravir-Based Antiretroviral Treatment and Once-Weekly Rifapentine and Isoniazid (3HP) for Tuberculosis Prevention in Antiretroviral-Naïve People with HIV: A Phase 1/2 Trial

Year: 2024

Type: preprint

Source: SSRN Electronic Journal

DOI: 10.2139/ssrn.4951990

Authors: Ethel Derby Weld, Trevor Beattie, Jayajothi Moodley, Manasa Mapendere, Isadora Salles, Belen Perez Solans, Bareng A.S. Nonyane, Lubbe Wiesner, Tanya Nielson, Vinodh Edward, Violet Chihota, Radojka M. Savic, Kelly E. Dooley, Richard E. Chaisson, Gavin Churchyard, DOLPHIN-TOO Study Team

Institutions: Johns Hopkins University, Aurum Institute, University of California, San Francisco, University of Cape Town, Vanderbilt University Medical Center

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4402485320

Cites:

Cited by:

Related to: 10